It’s 2026, and We Still Don’t Know Much About Long-Term GLP Use - Medscape
Google News • 1/20/2026 – 1/21/2026
Summary
In 2026, there is still limited knowledge about the long-term use of GLP (glucagon-like peptide) medications. A study indicates that weight tends to return rapidly after individuals stop using obesity medications. Reports suggest that most patients regain weight after discontinuing popular weight-loss drugs.
Advertisement
Lindy Score Breakdown (V4.2)
40d
Age
1
Sources
from cluster
930
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^930/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^930/48 = 0.000001) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (6/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 40 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
Everything you need to know about RFK Jr., MAHA, and ‘glypho-gate’
Stat News • 2 days ago
From ALS to dental floss: Here are the teams competing in STAT Madness 2026
Stat News • 2 days ago
STAT+: What stands between brain implants and FDA approval?
Stat News • 2 days ago
STAT+: The nation’s MAHA mom lands in Congress, with some uncomfortable questions
Stat News • 2 days ago
STAT+: Up and down the ladder: The latest comings and goings
Stat News • 1 day ago
Can an RFK Jr. action figure help cement the MAHA-MAGA alliance?
Stat News • 2 days ago
Listen: FDA turmoil, election intrigue, AI, and more
Stat News • 2 days ago
STAT+: FDA rejection is a reality check on agency rhetoric
Stat News • 2 days ago
Kansas’ new ID law could have health consequences for trans people
Stat News • 1 day ago
CMS announces pause on new durable medical equipment suppliers
Stat News • 2 days ago